The use of low molecular weight heparin (LMWH) in pregnancy;Die anwendung von niedermolekularen heparinen in der schwangerschaft

Geburtshilfe und Frauenheilkunde

Volumn 61, Issue 6, 2001, Pages 355-363

  Heilmann, L ^a   Rath, W ^b   Tempelhoff, G F V ^a   Harenberg, J ^c   Breddin, H K ^d   Schramm, W ^e  

^a Gesundheits und Pflegezentrum Russelsheim   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c I Medizinische Klinik   (Germany)

^d International Institute of Thrombosis and Vascular Diseases   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CERTOPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PREDNISONE; REVIPARIN; TINZAPARIN;

ANTIPHOSPHOLIPID SYNDROME; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; HUMAN; OSTEOPOROSIS; PRACTICE GUIDELINE; PREGNANCY; REVIEW; RISK BENEFIT ANALYSIS; SPONTANEOUS ABORTION; THROMBOPHILIA; VAGINA BLEEDING;

EID: 0034947821     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-15426     Document Type: Review

References (80)

1. Anticoagulation with low molecular weight heparin during pregnancy
2. Thromboembolism in pregnancy
3. Is there a safe anticoagulation protocol for pregnant women with prostetic valves?
4. Antikoagulation während der Schwangerschaft und im Wochenbett (Schweizerische Konsensus-Konferenz)
5. Bone density changes in pregnant women treated with heparin: A prospective, longitudinal study
6. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin
7. Impact of LMWH (Fraxiparin) on some indices of maternal and newborne hemostasis
8. Longterm use of LMWH (Fraxiparine) in pregnance with cardiac pathology
9. Outcome in treated pregnancies in women with antiphospholipid syndrome: An update of the Utah experience
10. Criteria for antiphospholipd syndrome: Early pregnancy loss, fetal loss, or recurrent pregnancy loss?
11. Autoimmune disorder
12. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy
13. Safety of withholding heparin in pregnant women with a history of venous thromboembolism
14. Low molecular weight heparin use during pregnancy: Issues of safety and practicality
15. What is the optimal management of pregnant women with valvular heart disease in pregnancy?
16. Anticoagulation of pregnant women with mechanical heart valves: A systematic review of literature
17. Danaparoid for the treatment of heparin induced thrombocytopenia
18. Epidemiological, immunogenetic and immunotherapeutic aspects of unexplained recurrent miscarriage
19. Pregnancy complicated by the antiphospholipid syndrome: Outcomes with intravenous immunoglobulin therapy
20. Immunotherapy for recurrent spontaneous abortion early pregnancy
21. Prevention of fetal death in the antiphospholipid antibody syndrom
22. Treatment of antiphospholipid syndrome in pregnancy
23. Pharmacokinetic profile of a low molecular weight heparin (Reviparin) in pregnant patients: A prospective study
24. Treatment of venous thromboembolism with Tinzaparin during pregnancy
25. Maternal mortality: Confidential enquiries into maternal deaths in the United Kingdom
26. Anticoagulation of women with prosthetic heart valves during pregnancy
27. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium
28. Thromboembolism and pregnancy
29. Anticoagulants during pregnancy
30. Use of antithrombotic agents during pregnancy
31. Thromboembolism in pregnancy: An overview
32. Invited commentary
33. Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrom
34. Genetic susceptibility to pregnancy-related venous thromboembolism: Roles of factor V Leiden, prothrombin G20210 A, and methylenetrahydrofolate reductase C677 T mutations
35. The special case of venous thromboembolism in pregnancy
36. Thrombosis in pregnancy: Maternal and fetal issues
37. Pregnancy complicated by heparin associated thrombocytopenia: Management by a prospectively in vitro selected heparinoid (ORG 10,172)
38. Treatment of heparin induced thrombocytopenia: An overview
39. Thromboembolieprophylaxe mit niedermolekularem Heparin in der Schwangerschaft
40. Heparinprophylaxe in der Schwangerschaft - Wann und womit?
41. Utilization of intravenous immunoglobulin therapy to treat recurrent pregnancy loss in the antiphospholipid syndrome: A review
42. Niedermolekulare Heparine in der Frauenheilkunde
43. Antiphospholipid-antibodies and other thrombophilic defects in patients with a history of early onset severe preeclampsia or HELLP-Syndrome
44. Management of heparin associated thrombozytopenia in pregnancy with subcutan Hirudin
45. Thromboprophylaxis with low molecular-weight heparin (Fragmin) in high risk pregnancies
46. Beta-2-Glykoprotein-1-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women
47. Detection and importance of anticardiolipin antibodies
48. Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies
49. Recurrent pregnancy loss: An update
50. Low molecular weight heparin and ASA-therapy in women with autoantibodies and unexplained recurrent fetal loss
51. Low molecular weight heparin for thromboprophylaxis during pregnancy in 2 patients with mechanical mitral valves replacement
52. Low-molecular-weight heparin for prosthetic heart valves: Treatment failure
53. A study of sixty pregnancies in patients with the antiphospholipid syndrome
54. Aktuelles management der thromboembolie in schwangerschaft und wochenbett
55. Thromboembolic prophylaxis with danaparoid (Orgaran) in a high-thrombosis-risk pregnant women with the history of heparin induced thrombocytopenia (HIT) and Widal's disease
56. The role of inherited thrombophilia in venous thromboembolism associated with pregnancy
57. Risk factors for pregnancy associated venous thromboembolism
58. Low molecular weight heparin (LMWH) in pregnant patients with prosthetic heart valves
59. Anticoagulant therapie of pregnant patients with prostetic heart valves: Rationale for a clinical trial of low-molecular weight heparin
60. Low-molecular-weight heparin after mechanical heart valve replacement
61. Randomized, placebo controlled trial of intravenous immune globulin (IVIG) in antiphospholipid syndrome (APS) in pregnancy A, Pregnancy loss study group Randomized, progress report
62. A multicenter, randomized, double-blind pilot study of IVIG therapy during pregnancy in women with antiphospholipid syndrome
63. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies
64. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)
65. Antiphospholipid-syndrome and pregnancy loss
66. Multicenter evaluation of nine comercal kids for the quantification of anticardiolipin antibodies
67. Risk factors for venous thrombotic disease
68. Thromboembolic disease in pregnancy
69. Safety of low-molecular-weight heparin in pregnancy: A systematic review
70. Meta-analysis with LMWH's
71. Retrospective evaluation of the safety and efficacy of low molecular weight heparin as thromboprophylaxis during pregnancy
72. Intravenous immunoglobulin therapy of antiphospholipid syndrom
73. Birth outcomes in pregnant women treated with low-molecular-weight heparin
74. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy
75. In-vitro- und In-vivo-Effekte polyvalenter Immunglobuline bei Patientinnen mit rezidivierenden Spontanaborten und antipaternalen non-HLA-Antikörpern
76. Successful treatment in two women with antiphospholipid antibodies and refractory pregnancy losses with intravenous immunoglobulin infusions
77. Heparin induced thrombozytopenia in patients treated with low molecular weight heparin or unfractionated heparin
78. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrom
79. Thromboembolische Komplikationen in Schwangerschaft und Wochenbett